Tumor long-axis diameter and SUVmax predict long-term responders in 90Y-ibritumomab tiuxetan monotherapy-Reference-Cited by-同舟云学术

Tumor long-axis diameter and SUVmax predict long-term responders in 90Y-ibritumomab tiuxetan monotherapy

Published:2018-09-10 Issue:1 Volume:109 Page:91-97
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Tsukamoto Norifumi,Yokohama Akihiko,Higuchi Tetsuya,Mitsui Takeki,Koiso Hiromi,Takizawa Makiko,Shimizu Hiroaki,Ishizaki Takuma,Matsumoto Morio,Toyama Kohtaro,Sakura Tohru,Ogura Hidemi,Saitoh Takayuki,Ishida Fumihiro,Murakami Hirokazu,Tsushima Yoshito,Handa Hiroshi

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

http://link.springer.com/article/10.1007/s12185-018-2526-z/fulltext.html

Reference29 articles.

1. Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol. 2005;23:8447–52.

2. Czuczman MS, Grillo-López AJ, White CA, Saleh M, Gordon L, LoBuglio AF, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol. 1999;17:268–76.

3. Watanabe T, Tobinai K, Shibata T, Tsukasaki K, Morishima Y, Maseki N, et al. Phase II/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin’s lymphoma: JCOG 0203 trial. J Clin Oncol. 2011;29:3990–8.

4. Robinson KS, Williams ME, van der Jagt RH, Cohen P, Herst JA, Tulpule A, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin’s lymphoma. J Clin Oncol. 2008;26:4473–9.

5. Tobinai K, Watanabe T, Ogura M, Morishima Y, Ogawa Y, Ishizawa K, et al. Phase II study of oral fludarabine phosphate in relapsed indolent B-Cell non-Hodgkin’s lymphoma. J Clin Oncol. 2006;24:174–80.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic Value of Heterogeneity Index Derived from Baseline 18F-FDG PET/CT in Mantle Cell Lymphoma;Frontiers in Oncology;2022-04-14

2. The standardized uptake value calculated from ¹¹¹In-ibritumomab tiuxetan single-photon emission computed tomography/computed tomography is a useful predictor of the clinical response in patients treated by ⁹⁰Y- ibritumomab tiuxetan therapy;Journal of Clinical and Experimental Hematopathology;2021

3. Predictive value of pre-treatment FDG PET in patients with non-Hodgkin lymphoma treated with radioimmunotherapy: a systematic review;Clinical and Translational Imaging;2019-06

4. Ibritumomab-tiuxetan-y-90;Reactions Weekly;2019-02